A new study just published in the Journal of Medical Economics titled “Application of a simple point-of-care test to reduce UK healthcare costs and adverse events in outpatient acute respiratory infections” found that the FebriDx® test could save the United Kingdom’s healthcare system up to £89 million a year on unnecessary antibiotics, and further its efforts in the fight against antimicrobial resistance.
The FebriDx test has received HealthCanada approval, Saudi Arabia FDA clearance, Singapore HSA registration, Pakistan DRAP registration and is CE marked for sale in Europe. At this time, FebriDx has not received U.S. Food and Drug Administration (FDA) clearance and is not commercially available in the United States. For more information on FebriDx, visit febridx.com.
Media contact: Saranova, LLC • [email protected] • +1.941.928.9025
Lumos Diagnostics Supports the Victorian Healthcare System by Providing FebriDx® for a Pilot Evaluation in the Triaging of Acute Respiratory Infection Patients
Lumos Diagnostics supports the Victorian healthcare system by providing FebriDx® for a pilot evaluation in the triaging of acute respiratory infection patients